304 related articles for article (PubMed ID: 32176629)
21. Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma.
Huang Q; Ji M; Li F; Li Y; Zhou X; Hsueh CY; Zhou L
Mol Cell Probes; 2023 Feb; 67():101895. PubMed ID: 36682577
[TBL] [Abstract][Full Text] [Related]
22. Quantification of plasma cell-free DNA levels in dogs with various tumors.
Tagawa M; Shimbo G; Inokuma H; Miyahara K
J Vet Diagn Invest; 2019 Nov; 31(6):836-843. PubMed ID: 31585514
[TBL] [Abstract][Full Text] [Related]
23. Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers.
Arko-Boham B; Aryee NA; Blay RM; Owusu EDA; Tagoe EA; Doris Shackie ES; Debrah AB; Adu-Aryee NA
Cancer Genet; 2019 Jun; 235-236():65-71. PubMed ID: 31105051
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery.
Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527
[TBL] [Abstract][Full Text] [Related]
25. Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer.
Benati M; Montagnana M; Danese E; Mazzon M; Paviati E; Garzon S; Laganà AS; Casarin J; Giudici S; Raffaelli R; Ghezzi F; Franchi M; Lippi G
Pathol Oncol Res; 2020 Oct; 26(4):2281-2289. PubMed ID: 32462419
[TBL] [Abstract][Full Text] [Related]
26. Plasma Cell-Free DNA Is a Potential Biomarker for Diagnosis of Calcific Aortic Valve Disease.
Ma W; Zhang W; Liu H; Qian B; Lai R; Yao Z; Wang Y; Yan Y; Yuan Z
Cardiology; 2024; 149(2):155-162. PubMed ID: 37899036
[TBL] [Abstract][Full Text] [Related]
27. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
Li B; Pu K; Ge L; Wu X
Gene; 2019 Sep; 714():143993. PubMed ID: 31330238
[TBL] [Abstract][Full Text] [Related]
29. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease.
Kumar S; Nadda N; Paul S; Gamanagatti S; Dash NR; Vanamail P; Saraya A; Shalimar ; Nayak B
Front Mol Biosci; 2022; 9():1024193. PubMed ID: 36483538
[No Abstract] [Full Text] [Related]
31. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer.
Ren S; Zeng G; Yi Y; Liu L; Tu H; Chai T; Hu L
Heliyon; 2023 Oct; 9(10):e20851. PubMed ID: 37860559
[TBL] [Abstract][Full Text] [Related]
32. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence.
Fawzy A; Sweify KM; El-Fayoumy HM; Nofal N
J Egypt Natl Canc Inst; 2016 Dec; 28(4):235-242. PubMed ID: 27634416
[TBL] [Abstract][Full Text] [Related]
33. [Value of the concentration and integrity of serum cell-free DNA for the clinical diagnosis of esophageal carcinoma].
Qiu YW; Shen XJ; Jin CJ; Cao XJ; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2018 Dec; 40(12):905-910. PubMed ID: 30605980
[No Abstract] [Full Text] [Related]
34. Clinical value of plasma cfDNA concentration and integrity in breast cancer patients.
Miao Y; Fan Y; Zhang L; Ma T; Li R
Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):64-72. PubMed ID: 31472049
[TBL] [Abstract][Full Text] [Related]
35. PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.
Murillo Carrasco A; Acosta O; Ponce J; Cotrina J; Aguilar A; Araujo J; Rebaza P; Pinto JA; Fujita R; Buleje J
J Clin Lab Anal; 2021 Apr; 35(4):e23720. PubMed ID: 33522650
[TBL] [Abstract][Full Text] [Related]
36. Cell Free DNA and Procalcitonin as Early Markers of Complications in ICU Patients with Multiple Trauma and Major Surgery.
Ahmed AI; Soliman RA; Samir S
Clin Lab; 2016 Dec; 62(12):2395-2404. PubMed ID: 28164563
[TBL] [Abstract][Full Text] [Related]
37. A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: sensitivity and specificity for the diagnosis of myocardial infarction.
Lou X; Hou Y; Liang D; Peng L; Chen H; Ma S; Zhang L
Int J Mol Med; 2015 Jan; 35(1):72-80. PubMed ID: 25374065
[TBL] [Abstract][Full Text] [Related]
38. Cell-Free Circulating DNA Integrity Based on Peripheral Blood as a Biomarker for Diagnosis of Cancer: A Systematic Review.
Cheng J; Tang Q; Cao X; Burwinkel B
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1595-1602. PubMed ID: 28830871
[No Abstract] [Full Text] [Related]
39. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
